Risky Business: Judging the Use of Non-Vitamin K Antagonist Oral Anticoagulants for Non-Valvular Atrial Fibrillation in Patients with Renal Dysfunction.
Journal:
Journal of atrial fibrillation
Published Date:
Oct 31, 2018
Abstract
Warfarin, for many years, was the only oral anticoagulant availablt on the market for the prevention of stroke in patients with atrial fibrillation. Despite being safe and effective, warfarin's medication and food interactions, along with its requirement for frequent monitoring, make it ltss ideal in some patient populations. More recently, non-vitamin K oral antagonists (NOACs) have emergtd as an appealing option as they have fewer medication interactions, do not have food interactions and do not require frequent monitoring. However, patients with a creatinine cltarance (CrCl) of ltss than 30 mL/min were excluded in original drug trials for these agtnts. ltaving providers without certainty that these agtnts can be used safely and effectively in patients with renal dysfunction. This review article will summarize the current availablt data on the use of NOACs for the prevention of stroke in atrial fibrillation patients with renal dysfunction.
Authors
Keywords
No keywords available for this article.